Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Emir CelikNilay Sengul SamanciMehmet KaradagNebi Serkan DemirciDuygu Ilke CikmanSumeyra DerinSahin BedirEzgi DegerliKerem OrucNihan Şentürk ÖztaşFuat Hulusi DemirelliPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
This research showed OS in patients with and without RI was comparable. Although not statistically significant, PFS in patients with classical mutation was approximately 6 months shorter in those with RI patients.